10/28/2021

speaker
Operator
Conference Call Operator

Good morning, and welcome to Avalo Biosciences conference call. Discussed is third quarter 2021 business highlights. At this time, all participants are in listen-only mode. Following the formal remarks, we will open the call up for your questions. Please be advised that this call is being recorded at the company's quest. At this time, I would like to turn the call over to Kendra Sweeney of Avalo. Please proceed.

speaker
Kendra Sweeney
Investor Relations Representative

Thank you. This morning, we issued a press release that outlines the topics we plan to discuss today. This release is available at www.ivelobio.com under the Investors tab. Today on our call, Simba Gill, Chief Executive Officer, Mark Bodmer, President of R&D and Chief Scientific Officer, and Jonathan Zung, Chief Development Officer, will review our recent business highlights and third quarter 2021 financial results. Before I begin, I would like to remind everyone that statements made during this conference call that do not relate to matters of historical fact, including statements about our objectives and anticipated clinical milestones, the impact of any of our product candidates, and the timing and results of any clinical studies should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are intended to be subject to the safe harbor protection provided by the Reform Act. Actual results could differ materially from those indicated by the forward-looking statements due to their impact of many factors. Participants are directed to the risk factors set forth in Avello's quarterly report on Form 10-Q for the quarter ended September 30, 2021, and the company's other filings with the Securities and Exchange Commission. Any forward-looking statements made today speak only to Avello's operations as of today. Avello disclaims any duty to provide updates to its forward-looking statements, even if subsequent events cause the company's views to change. It is now my pleasure to pass the call over to Simba.

speaker
Simba Gill
Chief Executive Officer

Thank you, Kendra. Good morning, everyone, and thank you for joining us to review our progress during the third quarter. A major news for the last quarter was, of course, the positive top-line results of our Phase II trial of EDP1815 in patients with mild and moderate psoriasis. The Phase II clinical data prove, beyond reasonable doubt, that we can indeed harness syntax to create medicines. I can't emphasize enough the importance and value of these data. The trial addressed a central question we have been asking since we first started to develop, Can targeting syntax be the foundation for a new profile of medicine? The answer is yes. With EDP1815, we have now shown in a well-controlled phase two clinical trial that we can harness syntax to make a clinical impact on patients with an oral product candidate with safety and tolerability data comparable to placebo. Together with affordable manufacturing, These data support the potential of syntax medicines to address an enormous unmet need in the global treatment of patients with mild and moderate inflammatory disease. The data from the phase two trial underscore two drivers of value. The first is the potential of EDP1815 as an important new medicine in the treatment of psoriasis. Based on the data, we are advancing EDP 1815 towards registration trials in mild and moderate psoriasis. The primary unmet need in psoriasis is for this segment of patients. There are over 55 million patients with psoriasis worldwide, and patients with mild and moderate disease represent over 90% of this patient population. The second driver of value is that this is proof of concept for the Syntax platform in a phase two clinical trial. The potential implications of this are immense. It reveals a previously unknown branch of biology which touches on a broad mechanism for the resolution of inflammation which impacts a considerable number of diseases and for which we have shown a new type of medicine that works in humans. In dermatology alone, there are globally over 200 million people who suffer from mild to moderate diseases for which there are limited treatment options. In broader inflammatory diseases, including arthritis, asthma, and chronic obstructive pulmonary disease, there are about a billion people worldwide in need of better treatment. I'd like to touch on one specific aspect of syntax-based products as a new type of medicine. We are developing orally delivered microbial products that are non-live biotherapeutics. This is a completely different concept, the live biotherapeutics and the microbiome. There is no colonization or modification of the microbiome. They have a direct pharmacological effect through interactions with host cells in the gut, which in turn modulates systemic inflammatory responses throughout the body via the small intestinal axis. The clinical responses to EDP 1815 opened the door both to EDP 1815 as a potentially important medicine in dermatology and to the broader potential of the platform. Our aim has always been to develop an entirely new profile of medicine that will transform healthcare rather than another incremental improvement to what already exists. We did not invent the small intestinal axis. We discovered it by inventing syntax medicines which harness this extraordinary natural system which controls inflammation throughout the body. What we have discovered is how to harness nature to create something that has never existed before. We have discovered and pioneered new principles and new approaches for developing and manufacturing syntax medicines. Our phase two data, together with other clinical and preclinical data we have generated, gives us high confidence that we will realize our vision to transform global healthcare. Let me repeat the core point. We have demonstrated that we can harness syntax to drive clinical effects throughout the body with an orally delivered gut-restricted agent. Syntax medicines are a substantial new platform in our industry with the potential to help hundreds of millions of patients globally at all stages of disease. Most of these patients have so far not received the benefits of biotech innovation. Think of this in terms of combining the discovery of cytokine biology with the discovery of therapeutic antibodies. Newly discovered biology underpinning many diseases together with the means to do something about it, and then delivering it to patients as a convenient oral pill. With that, I will hand over to Mark.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-